Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Pre-Tax Margin

Income before tax as a percentage of revenue.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -16.7%

Pre-tax margin was -16.7% in Q1 FY2026, down 27.3 pp from a year earlier. On a trailing-twelve-month basis it was -8.1%, up 16.4 pp year over year. Over 3 fiscal years it widened by 30.6 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-16.7%+2.8 pp QoQ
Last fiscal yearDec 2025
-1.6%+41.8 pp YoY
LTMMar 2026
-8.1%+16.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-27.3 pp——
1 year+41.8 pp——
3 years+30.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1.6%
Year-over-year change
+41.8pp

Pre-Tax Margin vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 pre-tax margin of -8.1% is the 3rd highest of the 7 companies compared; the peer median is -152.1%.
  • Its year-over-year change of +16.4 pp is the 4th highest of 6, against a peer median of +21.9 pp.
  • Over three fiscal years its change of +30.6 pp compares with a peer median of +217.7 pp.
AKBA Competitors Peer median
Pre-Tax Margin for AKBA and competitors
Company Period LTM level YoY 3-year change
ZVRAZevra Therapeutics, Inc.LTM Mar 2026109.1% +294.8 pp+345.2 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202640.7% +21.9 pp+90.1 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-8.1% +16.4 pp+30.6 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-121.8% ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-182.3% +766943.8 pp+3271.0 pp
PRTAProthena Corporation plcLTM Mar 2026-182.9% -98.9 pp-1840.8 pp
GOSSGossamer Bio, Inc.LTM Mar 2026-325.0% -284.6 pp—
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding AKBA) -152.1%+21.9 pp+217.7 pp

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.